Development of Cytokine Release Syndrome Is Associated with Superior Progression-Free Survival in DLBCL Patients Receiving Axi-Cel or Liso-Cel

Matthew Karr(University of California, San Francisco), Siobhan Larue(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Michael A. Spinner(Stanford Medicine), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Charalambos Andreadis(University of California, San Francisco), Sarah Wang(University of California, San Francisco), Madhav Seshadri(University of California, San Francisco)
Blood
November 2, 2023
10.1182/blood-2023-173885
Cited by 1

Related Papers

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487